You can buy or sell ONCE and other stocks, options, ETFs, and crypto commission-free!
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. Read More The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMar 20
Roche: Spark Deal Pricey But Accretive
No financial impact near term but clear cost synergies in the medium-long term, while the deal would ensure growth in the future.
Stock Price, News, & Analysis for Spark Therapeutics
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed ge...
Yahoo FinanceMar 12
SPARK THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
WILMINGTON, Del., March 12, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Do you own shares of Spark Therapeutics, Inc. (NASDAQ GS: ONCE )? Did you purchase any of your shares prior to February 25, 2019? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Spark Therapeutics, Inc. (“Spark” or the “Company”) (NASDAQ GS: ONCE) regarding possible breach...
Expected May 7, Pre-Market